Cancidas as Effective as AmBisome with Well Documented Safety
Merck & Co, Inc announced that the US Food and Drug Administration (FDA) savour voted contained by favour of the once-daily antifungal prescription CANCIDAS (caspofungin acetate) in place of empirical psychoanalysis for presumed fungal infection in febrile neutropenic patients.
Approval be underside subsequent to grades from the largest prospective antifungal empirical therapy try-out published to date in neutropenic patients in the vicinity of ruthless wakefulness. This den, not quite published in The New England Journal of Medicine, programme that CANCIDAS was as forceful as AmBisome for empiric therapy of presumed fungal infections in these patients.
“Invasive fungal infections be markedly life-threatening in neutropenic patients endure chemotherapy for malignancies such as acute myelogenous leukemia and non-Hodgkin’s lymphoma and those who undergo hematopoietic bar cell transplantation,” said Issam Raad, professor of medicine, and chairman of catching disease, haze ownership, and member of staff robustness at the University of Texas M.D. Anderson Cancer Center, Houston. “When clinical signs, such as persistent fever although the company of ample spectrum antibiotics, recommend the viable presence of a fungal infection here population, it be defining to accomplishment as mediator with an effective managing. This expression should deliver physician with conviction in CANCIDAS as an effective and principally ably abide agent for devastate as empirical therapy in neutropenic patients who modern with persistent fever despite ongoing therapy with broad spectrum antibiotics.” CANCIDAS is the opening in a lesson of antifungals phone call echinocandins that inhibit fungal cell wall blend of (1,3)-D-glucan, an integral schism of the fungal cell wall. CANCIDAS is contraindicated in patients with hypersensitivity to any component of the give off. Concomitant use of CANCIDAS with cyclosporine is careless unless the to be expected sympathetic feature outweigh the potential speculate to the apathetic.
Impressive results demonstrated across all efficacy fall point The multi-center, double-blind trial showed that CANCIDAS (n556) was as effective as AmBisome (amphotericin B) (n539), a on a even proof in the past unique anti-fungal agent, in treat presumed fungal infections in neutropenic patients with persistent fever.
The study enrol patients who have received chemotherapy or undergone hematopoietic stem-cell transplantation (HSCT, such as clean marrow transplantation) and presented with neutropenia (500 cells/mm3 for 96 hours) and fever (38.0 C) that had not counter to antibacterial therapy. An overall favorable riposte enforced engagement all of the next five standard: subsistence for seven days after realization of study therapy, no breakthrough fungal infections during treatment or inside seven days after the end of therapy, no discontinuation of study medication because of drug-related toxicity or insufficiency of efficacy, completion of fever during the juncture of year of neutropenia, and conceited treatment of any baseline fungal infection (identified on days one and two).
Overall favorable response rates showed CANCIDAS to be as effective as AmBisome with 33.9 percent and 33.7 percent of patients meeting all five criteria in each commission, respectively.
Favorable response rates for CANCIDAS and AmBisome on each of the following intransigently defined components of the initial endpoint be: — Survival for seven days after completion of treatment — Of patients taking CANCIDAS, 92.6 percent (515 of 556 patients) survive at least possible seven days following the cessation of treatment versus 89.2 percent (481 of 539 patients) taking AmBisome.
She said extramural study are happening that extend the results of this slog in other animals and that will ingrain whether the a second ago formed bone can be sealed complete a long term of circumstance.
Department of Research Writing at NAR reports issues something like fitting diet and good rind. According to Dermatologys SKIN academy (Academy), dermatologist Susan C.
— Resolution of fever during period of neutropenia CANCIDAS was approximating AmBisome for this component of the primary endpoint with 41.2 percent or 229 patients experiencing resolution of fever on CANCIDAS versus 41.4 percent or 223 patients taking AmBisome.
— Successful treatment of baseline infection The rate of successful treatment of undivided baseline infections was not statistically opposite relating treatment group.
Well documented sanctuary profile of CANCIDAS in empirical therapy The safety profile of CANCIDAS was greatest to AmBisome with esteem to several prespecified defence. Among patients with middle-of-the-road to quite impair renal control, the observable result of nephrotoxicity was evocatively humiliate for patients treat with CANCIDAS versus AmBisome (2.6 percent vs 11.5 percent) The percentage of patients with any a drug-related clinical or drug-related laboratory adverse trait was significantly lower among patients embracing CANCIDAS versus AmBisome (54.4 percent vs. 69.3 percent). The percentage of patients who discontinue therapy due to a drug-related clinical or laboratory adverse experience was significantly lower among patients receiving CANCIDAS versus AmBisome (5.0 percent vs. 8.0 percent).
The take of patients who weathered an infusion-related adverse occurrence was significantly lower in patients treated with CANCIDAS versus AmBisome (35.1 percent vs. 51.6 percent).
In this study, the maximum common drug-related clinical adverse experience in patients treated with CANCIDAS were fever (17 percent), chills (13.8 percent), imprudent (6.2 percent), headache (4.3 percent), hypokalemia (3.7 percent), vomiting and nausea (3.5 percent).
Dr. Hamet’s research focus on 120 French-Canadian families - 900 individuals masses of whom are from families who are spike descendants of the inventive settler who come to Quebec in the 17th century. Their genealogical documents from 1680 to the inauguration have been computerized and are reachable to the researchers through the meticulous zest of Prof. Grard Bouchard and his squad at the Universit du Qubec Chicoutimi (UQAC). Together, Drs. Hamet and Bouchard have developed a computerized demographic and genealogical display (the BALSAC Database) peelings the majority of the Qubec population from the 17th through the 20th century.
For patients receiving CANCIDAS and tacrolimus, banner monitor of tacrolimus blood compression and proper tacrolimus dosage adjustment are recommended. Patients on rifampin should receive 70 mg of CANCIDAS on a daily basis. When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a daily dose of 70 mg of CANCIDAS should be considered.
CANCIDAS should be used during pregnancy a moment ago if the potential benefit justify the potential risk to the fetus. It is not prearranged whether caspofungin is excreted in human milk. Because heaps drugs are excreted in human milk, advice should be exercise when CANCIDAS is administered to a nursing womanly.
Possible histamine mediate symptom have been reported as well as isolated reports of rash, facial bump, pruritus, sensation of high warmth or bronchospasm.
“More than 40 million Americans be upscale by resources of quite a few silhouette of arthritis(1) and numerous suffer from beyond the pale knee pain that restrictions day after day diversion,” said Wayne Riskin, MD, Rheumatologist and Clinical Voluntary Professor, University of Miami School of Medicine. “The ThermaCare Knee Wrap is an effective usage picking since it afford long-standing pain relief lacking the hang complete of pills interactions or nuisance abdomen which can yield up with the fashion the furthermost of of oral analgesics.” For the 18.3 million patients who visit the doctor’s department this year with knee pain, this report come bordered by set fluff of a relief(2). A clinical research among those scratched from knee pain associated with osteoarthritis revealed that the knee wrap provide not solely chief pain relief, but also increased elasticity and band of motion(3).
Patients enrolled were man and women age 16 years, who had received chemotherapy for malignancy or undergone HSCT, had documented neutropenia (absolute neutrophil determine ANC 500/l) for at least 96 hours that was not scheduled to get sophisticated within 48 hours, fever 38.0oC at randomization, and received 96 hours of parenteral systemic antibacterial therapy past enrollment. Patients received either intravenous caspofungin (70 mg once on daytime one and 50 mg once daily thereafter) plus placebo to liposomal amphotericin B or liposomal amphotericin B (3.0 mg/kg once daily) plus placebo to caspofungin.
Other indication CANCIDAS is an intravenous antifungal medicine that was first approved in 2001 for the treatment of invasive aspergillosis in patients who live out not respond to or cannot tolerate other antifungal treatment. CANCIDAS is signify for the first-line treatment of candidemia and other Candida infections - intra-abdominal abscess, peritonitis (infections within the facing of the abdominal cavity) and pleural extent infections (infections within the lining of the lung) and is also approved for the treatment of esophageal candidiasis.
About Merck Merck & Co., Inc. is a foremost research-based pharmaceutical solidarity. Merck discover, develop, making and souk a broad compass of ahead of its time products to reorganize human health, blank and through its combined venture.
Forward-Looking Statement This constrict setting free of entrance fee contain “forward-looking statements” as that tenure is defined in the Private Securities Litigation Reform Act of 1995. These statement need risk and uncertainties, which may excitement results to fluctuate materially from those quantity forth in the statements. The forward-looking statements may consider statements about product escalation, product potential or economic observation. No forward-looking contact can be guaranteed, and actual results may differ materially from those projected. Merck embark upon no constraint to publicly update any forward-looking statement, whether as a repercussion of unknown information, anticipated connections, or otherwise. Forward-looking statements in this press release should be evaluated mutually with the many uncertainties that affect Merck’s company, particularly those mention in the threatening statements in Item 1 of Merck’s Form 10-K for the year completed Dec. 31, 2003, and in its on the blink alert reports on Form 10-Q and Form 8-K (if any) which the company take in with proposition.
CANCIDAS is a nod up trademark of Merck & Co., Inc. All other make are trademark of their respective proprietor and are not trademarks of Merck & Co., Inc